South Korea’s cell and gene therapy landscape is highly dynamic, as observed from regulatory approvals, clinical trial progress, and manufacturing activity, from over 150 companies in active drug development. Additionally, with global pharma including Bayer, Novartis and more seeing strategic investments into the CGT space within South Korea, greater opportunities for scientific innovation and technology advancement are yet to come.
One Pass, Two Events: Part of the World Advanced Therapeutics Summit South Korea organized by Hanson Wade, this event offers a platform for cross-learning and connections with experts working in RNA and vaccine development and together establish South Korea as a global hub for advanced biopharma innovation.